Showing 51 news articles about Treatment simplification strategies

Filters Content type: Editors' picks Topic: Treatment simplification strategies

Research into HIV treatment strategies in which the number of antiretroviral drugs or frequency of dosing is reduced. Some dual therapy regimens have proven to be safe and effective.

Treatment simplification strategies

DTG/3TC vs TDF/FTC dual therapy: ALTAR study results too limited and too early to comment

Editor's pick
i-Base
6 December 2023
Hepatitis B

HBcAb positivity is a risk factor for failure to achieve complete virologic suppression of HIV-RNA after antiretroviral switch to 3TC+DTG

Editor's pick
NATAP
27 October 2023
Undetectable viral load & treatment as prevention

Two-Drug Regimen as Good as Three in Suppressing HIV in Semen and Rectum in Small Study

Editor's pick
TheBodyPro
22 August 2023
HIV treatment

IDWeek 2022 Study Bites: What’s New in HIV Antiretroviral Therapy

Editor's pick
TheBodyPro
10 November 2022
Changing treatment

Inflammatory Biomarkers in HIV Support Safety of Switching to 2-Drug Antiretroviral Therapy

Editor's pick
Infectious Disease Advisor
8 September 2022
Treatment simplification strategies

Macrophage Activation for 2 Years After Switch From 3 to 2 Antiretrovirals

Editor's pick
NATAP
5 August 2022
Changing treatment

Outcomes of HIV Virologic Suppression After Switching to Dolutegravir/Lamivudine

Editor's pick
Infectious Disease Advisor
28 March 2022
Treatment simplification strategies

Implications of historical M184V on use of dual dolutegravir/lamivudine ART

Editor's pick
i-Base
15 November 2021
New & experimental HIV treatments

HIV: Could Another Two-Drug Regimen Be on the Horizon?

Editor's pick
Medscape (requires free registration)
21 July 2021
Treatment simplification strategies

GSK's ViiV, armed with long-term Dovato data, eyes 'tipping point' for 2-drug HIV regimen

Editor's pick
FiercePharma
7 October 2020
Starting treatment

Dovato Shows Promise as a Rapid Test-and-Treat HIV Regimen

Editor's pick
POZ
1 September 2020
Treatment simplification strategies

As Two-Drug HIV Treatment Rises, Long-Term Inflammation Becomes a Potential Concern

Editor's pick
TheBodyPro
8 July 2020
HIV treatment

Top 10 HIV Clinical Developments of 2019

Editor's pick
TheBodyPro
27 November 2019
Treatment simplification strategies

Jitters Over New Two-Drug HIV Regimens

Editor's pick
Medscape (requires free registration)
12 November 2019
Low CD4 count

Two-Drug HIV Regimen Works Well Except in People With Low CD4 Count, Study Finds

Editor's pick
TheBodyPro
22 October 2019
Treatment simplification strategies

Some issues to consider with Dovato (dolutegravir + 3TC)

Editor's pick
CATIE
3 October 2019
Pharmaceutical industry

Can new Dovato data jump-start uptake of 2-drug HIV regimen? ViiV hopes so

Editor's pick
FiercePharma
24 July 2019
Cardiovascular disease

Efavirenz Dose Reduction Improves Lipid Profile in Adults With HIV-1

Editor's pick
Infectious Disease Advisor
19 June 2019
Treatment simplification strategies

FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

Editor's pick
Food & Drug Administration
9 April 2019
Treatment simplification strategies

ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks

Editor's pick
ViiV press release
5 April 2019
Treatment simplification strategies

Two-antiretroviral maintenance failure - raltegravir regimens seem most vulnerable

Editor's pick
NATAP
29 March 2019
Treatment simplification strategies

Laura Waters, MD, FRCP: Can Two Drugs Tango?

Editor's pick
Contagion Live
12 March 2019
Treatment simplification strategies

Early ART in HIV Possible Key to Dolutegravir Monotherapy Success

Editor's pick
Infectious Disease Advisor
15 February 2019
HIV treatment

Six advantages of dolutegravir

Editor's pick
Spotlight SA
28 January 2019